Michael Atkins🇺🇸 Treatment Strategy for Intermediate and poor-risk Kidney Cancer from AUC3 in Miami
Автор: OncoAlert 360
Загружено: 2026-01-22
Просмотров: 59
Описание:
We kick off Day 1 of AUC3 2026 with a must-watch session from Dr. Michael Atkins 🇺🇸, diving deep into treatment strategies for intermediate- and poor-risk metastatic clear cell RCC (ccRCC) — with a sharp focus on IO-IO combinations.
🔥 Key message:
It’s time to acknowledge that IO/TKI combinations may not serve the long-term interests of the majority of patients with metastatic cRCC. If our goal is to improve cure rates, the future lies in building on a pure immunotherapy (IO-IO) backbone.
💡 This isn’t just about science — it’s about what patients want, and what we should want for our patients.
📌 In this video, you’ll learn:
Why IO-IO strategies matter in intermediate & poor-risk disease
The limitations of IO/TKI combinations in long-term outcomes
How a pure IO backbone could reshape the future of metastatic ccRCC care
🎥 Essential viewing for oncologists, researchers, trainees, and anyone following advances in kidney cancer treatment.
👉 Subscribe to OncoAlert for real-time insights, expert commentary, and exclusive coverage from major oncology meetings worldwide.
#OncoAlert #AUC3 #AUC32026 #KidneyCancer #ccRCC #mRCC #Immunotherapy #IOIO #MedicalOncology #OncologyConference #CancerResearch #RenalCellCarcinoma
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
